OTLK PDUFA date : bevacizumab
13 business days to decision · 2026-07-29
Outlook Therapeutics, Inc.'s bevacizumab for Neovascular Age-related Macular Degeneration — FDA decision expected July 29, 2026.
Run-up into the PDUFA PDUFA 7/29/26 today $1.83 $0.198 Daily close so far, T-120 through today. High $1.83, low $0.198. Run-up to date +240.1%. Decision 7/29/26. Historical price action, not a forecast.
Key facts
PDUFA date 2026-07-29
Business days away 13
Drug / candidate bevacizumab
Indication Neovascular Age-related Macular Degeneration
Company Outlook Therapeutics, Inc.
Market-cap tier Micro
Cohort decision-day move (history) ±7% median
Cohort move is the historical median absolute decision-day move for this market-cap tier — history, not a prediction. See the full 2026 PDUFA calendar →
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio